AC
ALXN

Athanor Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Athanor Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-350,800
Closed -$64.4M – 440
2021
Q2 		$64.4M Buy
350,800
+199,581
+132% +$34.3M 2.31% 10
2021
Q1 		$23.1M Sell
151,219
-13,634
-8% -$2.11M 0.54% 36
2020
Q4 		$25.8M Buy
164,853
+160,237
+3,471% +$20.6M 0.59% 38
2020
Q3 		$528K Buy
4,616
+487
+12% +$52.5K 0.02% 329
2020
Q2 		$463K Buy
+4,129
New +$438K 0.02% 319

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Athanor Capital's ALXN Position: Q3 2021 in Review

Athanor Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 350,800 shares — an estimated $64.4M sold.

Athanor Capital first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $64.4M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Athanor Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Athanor Capital sold 350,800 Alexion Pharmaceuticals shares in Q3 2021, an estimated $64.4M.
  • Athanor Capital first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Athanor Capital's Alexion Pharmaceuticals position peaked at $64.4M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Athanor Capital's 13F filing for Q3 2021, filed 15 Nov 2021.